Gabapentin Tablet, Film Coated
Product Images NDC 55154-3357

8 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55154-3357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

Creatinine Clearance (Gabapentin Fig1)
A mathematical formula calculating creatinine clearance (CLCr), factoring age, weight, serum creatinine level, and gender adjustment for females. The formula is presented as a text panel, likely part of clinical or pharmacokinetic information related to drug dosing considerations.*
FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical Structure (Gabapentin Str)
Chemical structure of gabapentin, depicting a cyclohexane ring with an aminomethyl group and a carboxymethyl group attached to the same carbon atom.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over 8 weeks. It compares placebo and gabapentin 3600 mg/day during a 4-week dose titration period followed by a 4-week fixed dose period. The gabapentin group shows a decreasing pain score trend, while the placebo group remains relatively stable.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)
Line graph showing weekly mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows weeks from baseline through week 7, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores generally decreasing more in the Gabapentin groups than placebo.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. The x-axis labels include Placebo (PBO), Gabapentin (GBP) 3600 mg for Study 1, and Placebo (PBO), Gabapentin (GBP) 1800 mg and 2400 mg for Study 2. The y-axis represents percentage response from 0% to 100%. Bars indicate higher responder proportions with gabapentin doses compared to placebo with statistical significance noted.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
A scatter plot illustrating the responder rate in patients aged 12 years and older with partial seizures, showing the difference in response percentage from placebo by daily dose (mg) for Gabapentin across three adjunctive therapy studies labeled Study a, Study b, and Study c. The x-axis represents daily dose in mg; the y-axis displays the difference in responder rate percentage.*
FDA Label Image

600mg Bag Label (07b005ac D21a 4ed4 A619 38bc75cdd139 01)

600mg Bag Label (07b005ac D21a 4ed4 A619 38bc75cdd139 01)
Gabapentin Tablets USP 600 mg film-coated oral tablets, unit dose package containing 10 tablets. The label includes storage instructions, warnings about child resistance and institutional use, and dispensing guidance. Manufactured by Aurobindo Pharma Limited, made in India, and distributed by Major Pharmaceuticals and Cardinal Health.*
FDA Label Image

800mg Bag Label (07b005ac D21a 4ed4 A619 38bc75cdd139 00)

800mg Bag Label (07b005ac D21a 4ed4 A619 38bc75cdd139 00)
Gabapentin Tablets, USP 800 mg film-coated tablets package label showing a count of 10 tablets. The label includes a barcode, storage instructions, a warning that the package is not child resistant and for institutional use only, and distributor information for Aurobindo Pharma USA, Major Pharmaceuticals, and Cardinal Health.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.